# DOC1021

Source: https://onco.cc/drugs/doc1021/  
OnCo record `doc1021` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.

## Summary

DOC1021 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Diakonos Oncology Corporation, in glioma & glioblastoma, melanoma. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: DOC1021
- Modality: Cancer vaccine
- Mechanism: A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.

## Sources

- ClinicalTrials.gov: trials of DOC1021: https://clinicaltrials.gov/search?intr=DOC1021

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Diakonos Oncology](https://onco.cc/companies/diakonos-oncology/)
- trials: [DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma](https://onco.cc/trials/nct07288112/), [DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)](https://onco.cc/trials/nct06805305/)

---
JSON: https://onco.cc/api/v1/entities/doc1021.json